drugset

drugset / Trial / NCT07051252

A Study of HBS-201 (Pitolisant Delayed-release)

NCT07051252 ↗

Phase 1 Completed 46 enrolled Harmony Biosciences Management, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy.

Timeline

Start: 2025-05-21
Primary completion: 2025-10-13
Completion: 2025-10-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HBS-201	Unknown	35.6 mg	Oral

Indications